Human Kruppel-like factor 2 (KLF2) is a Cys 2 /His 2 zinc-finger-containing transcriptional factor, which is involved in multiple cellular pathways. Utilizing gene expression profiling to identify aberrantly expressed genes in ovarian cancer, we found that KLF2 was significantly and specifically downregulated in ovarian tumors. After reintroducing KLF2 into ovarian cancer cell lines, we observed decreased cell growth and increased sensitivity to DNA damage-induced apoptosis. Analysis of genes that could be potential targets of KLF2 revealed that KLF2 negatively regulated WEE1 expression. WEE1 encodes a tyrosine kinase that regulates the G2/M cell cycle transition. Expression of KLF2 markedly repressed the transcription of WEE1 by directly binding to an SP1/ CPBP motif located between À252 bp and the start codon of the WEE1 promoter. Both activation and zincfinger domains of KLF2 were required for this suppression of Wee1 expression. In addition, we demonstrated that Wee1 expression prevents cancer cells from undergoing apoptosis in response to DNA damage; however, this resistance was abolished by coexpression of KLF2, which inhibits WEE1 transcription. Thus, the level of WEE1 is regulated by KLF2 and enhanced KLF2 expression sensitizes cells to DNA damage-induced apoptosis.
Introduction
Human Kruppel-like factors (KLFs) are a family of Cys 2 /His 2 zinc-finger transcriptional factors with considerable homology to Drosophila Kruppel factors, and they play diverse roles in cell proliferation and differentiation (Bieker, 2001; Black et al., 2001) . Two members of the KLF family, KLF4 and KLF6, have been demonstrated to play important roles in cell cycle regulation and cancer development (Bieker, 2001) . Both KLF4 and KLF6 are mutated or downregulated in multiple cancers including T-cell leukemia, colorectal cancer, bladder cancer, hepatocellular carcinoma and prostrate cancer (Chen et al., 2003a; Vax et al., 2003; Ito et al., 2004; Kimmelman et al., 2004; Kremer-Tal et al., 2004; Pandya et al., 2004; Reeves et al., 2004; Zhao et al., 2004) . Reintroduction of either KLF4 or KLF6 results in growth arrest and cell cycle regulation by regulating the expression of important cell cycle checkpoint genes, including p21/WAF1, CDK, etc (Zhang et al., 2000; Narla et al., 2001; Chen et al., 2003b; Yoon et al., 2003; Benzeno et al., 2004; Kimmelman et al., 2004) .
Our interest in KLF2 stems from our gene expression profiling using Affymetrix arrays to identify genes that were aberrantly expressed during the development of ovarian cancer. Analysis of microarray data revealed that KLF2 was abundantly expressed in normal ovarian epithelial cells, but significantly downregulated in ovarian cancers of different stages and grades. These results suggest that KLF2 might be an important gene involved in the development of ovarian cancer. KLF2 has been shown to be involved in endothelial cell differentiation (Dekker et al., 2002; Huddleson et al., 2004; SenBanerjee et al., 2004) and in programming quiescence of T cells as well as their survival in peripheral lymphoid organs and blood (Kuo et al., 1997; Buckley et al., 2001) . KLF2 shares strong homology in its C-terminal domain with other KLF members, which all bind to very similar DNA 'GT box', 'CACCC element' or Sp1-like motifs (Bieker, 2001; Black et al., 2001) . KLF2 can function as a transactivator or repressor, and several genes have been identified as targets of KLF2, including nitric oxide synthase (NOS) (SenBanerjee et al., 2004) , peroxisome proliferator-activated receptor-gamma (PPAR-g) (Banerjee et al., 2003) and the Vav proto-oncogene (Denkinger et al., 2001) . Recently, KLF2 was found to inhibit leukemia cell growth by upregulating the G1/S checkpoint gene p21/WAF1 (Wu and Lingrel, 2004) .
When we introduced KLF2 into ovarian cancer cell lines with very low endogenous KLF2 expression, we found that these cells had reduced growth rates and higher sensitivity to DNA damage-induced apoptosis. It led us to hypothesize that KLF2 might regulate DNA damage checkpoint gene expression. After measuring the expression of several cell cycle checkpoint genes including p53, p21, ATM, p27, p57, WEE1 and cyclins, we found that in addition to upregulating p21 gene expression as has been previously reported (Wu and Lingrel, 2004) , KLF2 also negatively regulated the expression of the human WEE1 gene.
Wee1 is a tyrosine kinase that controls the timing of the cell cycle. During cell cycle progression, M-phasepromoting factor (MPF), which is a complex of cdc2 and cyclin B, directly regulates the G2/M transition. The activated MPF is obligatory for entry into mitosis and is also required for DNA damage-induced apoptosis (Rowley et al., 1992; Tourret and McKeon, 1996; Elder et al., 2001; Li et al., 2002; Wang et al., 2004) . Wee1 negatively regulates the MPF complex by phosphorylating cdc2 on a conserved tyrosine (Tyr15), which causes aberrant mitosis and resistance to DNA damageinduced apoptosis (Rowley et al., 1992; Tourret and McKeon, 1996; Elder et al., 2001; Li et al., 2002; Wang et al., 2004) . Thus, we hypothesized that inhibition of WEE1 expression by KLF2 might contribute to the increased sensitivity to apoptosis.
In this report, we described significant and specific downregulation of KLF2 in ovarian cancer. We also showed that reintroduction of KLF2 gene into ovarian cancer cells modulated cell proliferation and increased DNA damage-induced apoptosis. We also demonstrated that the repression of WEE1 transcription by KLF2 contributes to part of the mechanism through which KLF2 sensitizes cancer cells in response to DNA damage by facilitating cells to undergo apoptosis.
Results

KLF2 is specifically downregulated in ovarian cancers
Eight normal ovarian specimens and 23 serous ovarian tumor specimens were microdissected to yield normal and tumor epithelial cell populations. RNA from these samples was then labeled and hybridized to Affymetrix U133A Gene Expression Profiling Chips. Analysis of these microarray data showed that KLF2 was significantly downregulated in different stages and grades of ovarian cancer (Figure 1a) . We also performed semiquantitative reverse transcriptase PCR (RT-PCR) to verify the microarray data in ovarian cancer cell lines and primary tumors. As shown in Figure 1b , KLF2 mRNA is downregulated in four out of six ovarian cancer cell lines and in most of the primary ovarian tumors. Given the fact that KLF4 and KLF6 have been implicated in the development of multiple cancers, we also assessed the expression level of KLF4 and KLF6 in ovarian samples. Analysis of the microarray data showed that there was no significant change of KLF6 between normal samples and primary tumors, whereas KLF4 was slightly downregulated in primary tumors. However, by use of semiquantitative RT-PCR, we did not observe the mRNA level change of KLF4 and KLF6 in ovarian cancer cell lines and primary tumors (data not shown). These data indicate that the loss of KLF2 was specific in ovarian cancer.
Reintroduction of KLF2 into ovarian cancer cell lines modulates cell proliferation and increases sensitivity to DNA damage-induced apoptosis
We generated stable KLF2-expressing ovarian cell lines KLF2-OV202 and KLF2-SKOV3. The expression level of KLF2/myc in these two cell lines was measured by use of immunoblotting with anti-myc antibody as shown in Figure 2a . To detect whether KLF2 expression affects cell growth, we performed proliferation assays on vector-only and three independent KLF2-expressing clones of each cell line. As shown in Figure 2b , KLF2-expressing clones proliferated more slowly than vectortransfected clones. To examine the effects of KLF2 on apoptosis, stable KLF2-expressing cells and vector-only transfectants were treated with methanesulfonate (MMS) and mitomycin C (MMC) to induce DNA damage. Cells were stained with DAPI under conditions where these agents preferentially enter apoptotic cells, and morphological changes associated with apoptosis (nuclear fragmentation) were detected by use of fluorescence microscopy ( Figure 3a) . Meanwhile, the protein levels of caspase 9 and PARP were also detected by use of immunoblotting (Figure 3b ). This analysis showed that KLF2-expressing cells had a higher percentage of apoptotic cells than that of vector-only transfectants in two different treatments. For example, when treated with 50 mg/ml MMS, 12% of vector-only OV202 cells underwent apoptosis, while 28% of KLF2-OV202 cells underwent apoptosis. The same results were also observed in MMC treatments. Immunoblotting assay also revealed that KLF2-expressing ovarian cell lines were more susceptible to DNA damage-induced apoptosis, as we observed strong cleavage of caspase 9 and PARP in KLF2-expressing clones. This suggested that KLF2 sensitized cells to MMS-and MMC-induced apoptosis.
Endogenous WEE1 expression was repressed by KLF2 expression in ovarian cell lines Because a number of cell cycle checkpoint genes, including p53, p27, cyclins, p21 and WEE1, are involved in the DNA damage response, we sought to investigate whether KLF2 affects the expression of these checkpoint genes. After transfecting KLF2 into HeLa and HEK293 (Figure 4a ). The same results were also observed in KLF2-expressing ovarian cell lines, as the expression of KLF2 markedly reduced the mRNA level of WEE1. Moreover, the expression of Wee1 protein was also decreased in the presence of KLF2 expression as shown by use of immunoblotting. The endogenous level of phosphorylated Cdc2 (Tyr15) but not total Cdc2 was also decreased due to the downregulation of WEE1 (Figure 4b ).
KLF2 inhibits WEE1 promoter activity
To determine whether the observed decrease in WEE1 mRNA resulted from transcriptional repression, we generated luciferase reporter constructs to measure WEE1 promoter activity in KLF2-transfected HeLa cells. A series of WEE1 promoter fragments were generated to sublocalize the potential KLF2 interacting region, as indicated in Figure 5a . Analysis of luciferase activity revealed that the highest WEE1 promoter activity was not obtained with the p1100-Luc construct but with the (Figure 5a ). This suggests that other transcriptional factors may also repress WEE1 promoter activity by binding to this region. To eliminate the interference from other transcriptional repressors and to acquire the highest promoter activity, we used the p630-Luc construct for further studies. The promoter truncation assay revealed that the potential KLF2 interacting region on the WEE1 promoter is located within the minimal promoter region between -252 and the start codon, as indicated by a four fold decrease of WEE1 promoter activity in the presence of KLF2 (Figure 5a ). We also found that KLF2 inhibited WEE1 promoter activity in a dose-dependent manner (Figure 5b ), as the highest inhibition was observed with 1.0 mg of KLF2 plasmid.
KLF2 directly binds to the SP1/CPBP motif within the WEE1 promoter
We utilized the chromatin immunoprecipitation (ChIP) assay to detect the potential in vivo interaction between the KLF2 protein and the WEE1 promoter. HEK293 cells were transiently transfected with KLF2/myc and the precipitated DNA was amplified with primers that span a 252 bp fragment upstream of the WEE1 start codon. As shown in Figure 6a , a ChIP PCR product was detected in the DNA-protein complex precipitated with anti-myc antibody. No significant amplification was detected in the samples precipitated with mouse IgG or Detection of caspase 9 and PARP protein cleavage after MMS-induced apoptosis. KLF2-expressing and vector-only OV202 and SKOV3 cells were treated with MMS (25 mg/ml) for 8 h, and then the total protein was collected and subjected to immunoblotting to detect the cleavage of caspase 9 and PARP protein. As shown in the figure, KLF2-expressing cells were more susceptible to DNA damage-induced apoptosis Figure 4 KLF2 expression suppresses endogenous WEE1 synthesis. Total RNA and total cellular protein were collected from KLF2-expressing and vector-only SKOV3, OV202, HeLa and HEK293 cells. (a) Semiquantitative RT-PCR was performed to detect mRNA levels of WEE1 and KLF2 genes. GAPDH mRNA was used as an internal control. (b) Immunoblotting was performed using total cellular protein to detect the expression level of KLF2, Wee1, total Cdc2 and phosphorylated Cdc2 (Tyr). Actin was used as an internal control. As shown in the figure, KLF2 expression decreased WEE1 mRNA and protein level, and in parallel, as the downstream target of Wee1, the level of phosphorylated Cdc2 (Tyr) was also decreased in the presence of KLF2
Transcriptional repression of WEE1 and apoptosis F Wang et al in the control without antibody. Actin was used as a negative control. The WEE1 promoter À252 fragment contains several potential binding sites for KLF2, including a GC box, zinc-finger/POZ domain, as well as SP1/Core promoter binding protein (CPBP, with three Kruppel-type zincfingers) motif. To define precisely the binding site of KLF2, we analysed WEE1 promoter activity with mutations in each of these elements. As shown in Figure 6b , each of these mutations showed decreased promoter activity. In particular, mutation of the SP1/ CPBP motif (CCCGCCCCC) reduced promoter activity by 40% and this mutation also abolished the ability of KLF2 to repress WEE1 promoter activity. We further performed electrophoretic mobility shift assays (EMSAs) to detect the interaction of KLF2 protein with the three putative binding sequences. Nuclear extracts from KLF2-expressing SKOV3 cells and vector-only SKOV3 cells were used. As shown in Figure 6c , we observed shifted DNA-protein complex bands with the wild-type Sp1/CPBP fragment, not with the other two putative binding motifs. Meanwhile, the mutated Sp1/CPBP motif abolished KLF2 binding ability. When anti-myc antibody was incubated together with KLF2/myc and SP1/CPBP fragment, we observed a further shifted band (supershift) of protein-DNA complex. These data indicate that KLF2 specifically binds to the Sp1/CPBP motif on WEE1 promoter.
KLF2's repression of the WEE1 promoter requires both the activation and the zinc-finger domains
Previous studies demonstrated that KLF2 protein contains three different domains: activation domain Figure 5 WEE1 promoter activity is inhibited by KLF2. (a) A series of truncated WEE1 promoters were subcloned into pGL3 basic vector to generate luciferase reporter system activated by WEE1 promoters. The following truncations were tested: p1100-Luc, p871-Luc, p630-Luc, p555-Luc, p386-Luc, p315-Luc and p252-Luc. HeLa cells were transiently transfected with luciferase reporter vectors and KLF2. At 36 h after transfection, cells were lysed and analysed for luciferase activity to measure the promoter activity in the presence or absence of KLF2. As shown in the figure, the highest promoter activity was obtained in the p630-Luc vector, and the potential KLF2 binding motif was within the minimal promoter region between À252 and the start codon. (b) HeLa cells were transfected with p630-Luc and an increasing amount of KLF2 plasmids. At 36 h after transfection, the luciferase activity assay was performed as above. As shown, the repression of WEE1 transcription by KLF2 was dose-dependent Transcriptional repression of WEE1 and apoptosis F Wang et al (amino acids 1-110), autoinhibitory domain (amino acids 111-267) and the zinc-finger DNA binding domain (amino acids 268-354). To identify which domain is involved in the transcriptional repression of the WEE1 promoter, we generated a group of constructs with various deletions of the KLF2 domain as shown in Figure 7a . The various KLF2 constructs were cotransfected with p630-Luc, and the luciferase activity was analysed as previously described. As indicated in Figure 7b , only the full-length KLF2 and the construct containing both the activation and the zinc-finger domain decreased WEE1 promoter activity. Constructs lacking either activation or zinc-finger domains did not repress the WEE1 promoter. These data suggest that both activation domain and zinc-finger domain are required in the repression of WEE1 transcription.
Downregulation of WEE1 by KLF2 is involved in DNA damage-induced apoptosis
To test whether the repression of WEE1 by KLF2 contributes to the increased apoptosis induced by DNA damage, we generated a WEE1 ectopic expression construct, in which the expression of WEE1 is activated by its own À630 promoter fragment. Vector-SKOV3 and KLF2-SKOV3 cells were transfected with p630-Wee1 and then treated with MMS (25 mg/ml) for 8 h. As shown in Figure 8a , we observed abundant Wee1 expression in SKOV3 cells. However, Wee1 expression was suppressed in KLF2-expressing SKOV3 cells due to the repression of WEE1 promoter activity. . At 48 h after transfection, ChIP assay was performed to detect the direct binding of KLF2 on WEE1 promoter. Anti-myc antibody, mouse IgG, was used to precipitate the DNA-protein complex. The precipitated DNA fragment was amplified with the primers spanning À252 bp region upstream of the WEE1 start codon. Actin was used as control. (b) Site-directed mutagenesis of p252-Luc vector containing three independent mutations revealed that KLF2 binds to SP1/CPBP motif on WEE1 promoter. (c) EMSA was conducted to detect the direct interaction between KLF2 protein and SP1/CPBP DNA fragment in vitro. As shown in the figure, of the three putative binding motifs including GC box, Zinc-finger/POZ and SP1/CPBP, KLF2 only binds to SP1/CPBP motif. And the mutation of SP1/CPBP motif abolishes the binding ability of KLF2. SS, supershift band as a complex of anti-myc antibody, KLF2 protein and oligos; S, shift band of KLF2-oligo complex; NS, nonspecific band (Figure 8b) . Consistent with previous studies (Pendergast, 1996; Wang et al., 2004; Yuan et al., 2004) , Wee1 expression markedly inhibited the percentage of apoptotic cells. It was observed that after MMS treatment, the percentage of apoptotic cells in Wee1-SKOV3 cells was 5.66% versus 9.35% in vector-only SKOV3 cells. Meanwhile, KLF2 expression markedly increased the sensitivity of SKOV3 cells to MMS-induced apoptosis, as we observed that 24.34% cells underwent apoptosis after MMS treatment. We also found that the apoptotic resistance by Wee1 was suppressed by the coexpression of KLF2 due to the repression of WEE1 transcription (Figure 8b ).
Discussion
The Kruppel-like gene family is a group of transcriptional regulators that have been shown to play important roles in cell proliferation and differentiation. Alterations of KLFs expression have been shown to be involved in the development of many solid tumors as well as leukemia and lymphomas (Chen et al., 2003a; Vax et al., 2003; Ito et al., 2004; Kimmelman et al., 2004; Kremer-Tal et al., 2004; Pandya et al., 2004; Reeves et al., 2004; Zhao et al., 2004) . In this study, we found that KLF2 was significantly downregulated in ovarian tumors and overexpression of KLF2 sensitized cells to DNA damage-induced apoptosis.
When we reintroduced KLF2 into ovarian cancer cell lines, we found that KLF2 inhibited cell proliferation and also increased the sensitivity to DNA damageinduced apoptosis. We analysed a number of cell cycle checkpoint genes that are involved in response to DNA damage and found that KLF2 negatively regulated the expression of WEE1. KLF2 binds to the Sp1/CPBP motif on the WEE1 promoter both in vitro and in vivo. Mutation of this motif not only diminished the binding activity of KLF2, but also decreased the basal promoter activity. It is suggested that KLF2 may be competing with other transcriptional activators to bind to this motif, resulting in the repression of WEE1 basal promoter activity and substantial decreases of both WEE1 mRNA and protein levels. KLF2 suppresses the expression of WEE1 in a dose-dependent manner, and both the activation and zinc-finger domains of KLF2 are required to repress WEE1 expression.
Analysis of the WEE1 promoter sequence also suggested that other transcriptional factors might interact with this promoter between nucleotides -871 When these experiments were in progress, Wu and Lingrel (2004) reported that KLF2 inhibited Jurkat T leukemia cell growth via directly transactivating p21/ WAF expression. Thus, KLF2 is the third member of the KLF family, in addition to KLF4 and KLF6, which can upregulate the expression of p21. Our study has demonstrated that not only can KLF2 regulate a G1/S checkpoint gene, but it also plays a role in G2/M checkpoint control. At the G1/S checkpoint, KLF2 transactivates p21/WAF to prevent cells from entering S phase in the presence of DNA damage. Meanwhile, KLF2-mediated G2/M checkpoint control also promotes cells to undergo apoptosis in response to DNA damage. The G2/M checkpoint is regulated by the MPF complex (cdc2/cyclinB). Activated cdc2/cyclinB is obligatory for entry into mitosis and is also required for DNA damage-induced apoptosis (Rowley et al., 1992; Tourret and McKeon, 1996; Elder et al., 2001; Li et al., 2002; Wang et al., 2004) . This pathway is often defective in some cancer cell lines due to the sustained inactivation of Cdc2 kinase, and the phosphorylation of Cdc2 at Tyr-15 by Wee1 contributes mainly to the inactivation of MPF complex. Thus, it is possible that depletion of WEE1 by KLF2 allows cells to initiate DNA damageinduced apoptosis more efficiently, while the presence of Wee1 arrests cells at G2/M to provide sufficient DNA repair, therefore prolonging cell viability.
There are many similarities between KLF2, KLF4 and KLF6. First, these three proteins have very high homology in their C-terminal DNA binding domains. Thus, they may share similar target genes in addition to p21/WAF. For example, in a gene profiling experiment to investigate the potential role of KLF4 in cell cycle regulation, Chen et al. (2003b) found that KLF4 can also suppress the expression of WEE1 mRNA. Meanwhile, alterations in all three genes are found in multiple cancers, and re-expression of KLF2, KLF4 or KLF6 results in growth arrest and cell cycle control by regulating the expression of important cell cycle checkpoint genes. Therefore, all three genes may play important roles in cancer development. A better understanding of the mechanisms whereby these KLFs regulate gene expression could be used for designing drugs that affect tumor-specific transcription.
In conclusion, our studies have revealed that KLF2 may function to repress cancer cell growth. The expression of KLF2 modulates cell proliferation and regulates apoptosis in response to DNA damage. We have shown that the interaction of KLF2 with SP1/ CPBP motif on the WEE1 promoter results in the repression of WEE1 transcription. We have also demonstrated that KLF2's ability to repress WEE1 transcription represents part of the mechanism whereby KLF2 sensitizes cancer cells to DNA damage-induced apoptosis. This study may provide us with new therapeutic strategies to treat cancer cells that have alterations in the KLF family of genes.
Materials and methods
Microarray gene expression and data analysis
Target cells from ovarian tumor or normal ovarian tissue were enriched by manual microdissection under a dissecting microscope. The purity of cancer cells obtained was greater than 80%. Total RNA was extracted from the microdissected target cells using the RNeasy Micro Kit according to the manufacturer's protocol (Qiagen, Valencia, CA, USA). The quality of all RNA samples was checked using the RNA 6000 Nano LabChip kit and Agilent 2100 bioanalyser (Agilent Technologies Inc., Palo Alto, CA, USA). Human genome HG-U133A chips (Affymetrix, Santa Clara, CA, USA) and GeneChip Eukaryotic small sample target labeling assay (Affymetrix) were used to perform microarray assays. All subsequent labeling, fragmentation and hybridization were carried out using standard Affymetrix protocols. Raw data were normalized and analysed using GeneSpring 7.1 (Silicon Genetics, Redwood City, CA, USA), and using both RMA (Robust Multi-chip) and GC-RMA algorithms to normalize CEL files before any filtering was performed.
Amplification of the human KLF2 cDNA and human WEE1 promoter Full-length human KLF2 cDNA was amplified using RT-PCR from human keratinocyte total RNA. Various KLF2 mutations were generated by PCR from full-length KLF2 cDNA. All mutations were confirmed by sequencing. Primers for KLF2 cDNA and mutations are listed in Table 1 . The human WEE1 gene promoter was amplified by PCR from human keratinocyte genomic DNA. The amplified WEE1 promoter spanned À1100 bp upstream of the start codon and was confirmed by sequencing. A series of deletions of the WEE1 promoter were generated to identify the interacting motif of KLF2. Primers for WEE1 promoter cloning are listed in Table 2 . Different fragments amplified from the WEE1 promoter were named according to the start site upstream of the start codon, such as À1100, À871, etc.
Plasmid construction
The eucaryotic expression plasmid for human KLF2 was generated by the insertion of the KLF2 cDNA (digested with EcoRV and XbaI) into the pcDNA3.1/myc-his vector (Invitrogen, Carlsbad, CA, USA) to construct a myc-tagged KLF2 expression vector. Different mutations of KLF2 were also inserted into the same vector to generate various KLF2 mutations tagged with myc. For the WEE1 promoter, the primers introduced, respectively, a KpnI and a HindIII restriction site on the 5 0 -and 3 0 -end of the amplified fragment. The PCR products of À1100 bp and various truncations of the WEE1 promoter were digested with KpnI and HindIII, and then subcloned into appropriately digested luciferase reporter gene vector pGL3-Basic (Promega, Madison, WI, USA) to generate WEE1 promoter-activated luciferase reporters. Different truncations were named according to the WEE1 promoter as p1100-Luc, p871-Luc, p630-Luc, etc.
A Wee1 ectopic expression vector was generated to express human wild-type WEE1 activated by the WEE1 promoter containing a 630 bp fragment upstream of the WEE1 start codon. The cDNA for wild-type WEE1 was generously provided by Dr Helen Piwnica-Worms (Howard Hughes Medical Institute, Washington University School of Medicine). The p630-Luc vector was digested with HindIII and XbaI to remove the LUC gene (p630-Luc À ), and the appropriately digested wild-type WEE1 gene was inserted into the p630-Luc À vector to generate a p630-WEE1 construct, in which the WEE1 gene was transcribed from its own promoter.
Cell culture and transfection OV167, OV177, OV202 and OV207 ovarian cancer cell lines and the short-term cultures of the normal ovarian epithelium (VOSE) were established at the Mayo Clinic (Dent and Grant, 2001 ). Ovarian cancer cell lines SKOV3 and OVCAR5, as well as HeLa and HEK293 cells, were obtained from the American Type Culture Collection (Manassas, VA, USA). All cells were grown according to the manufacturer's recommendations. Transient transfection and stable transfection were performed using Fugene6 reagent (Roche, Indianapolis, IN, USA) according to the manufacturer's protocol. For stable transfection, cells were grown in selective medium containing 200 mg/ ml geneticin (OV202) and 800 mg/ml geneticin (SKOV3) for 2-3 weeks. Individual colonies were subsequently cloned using cloning cylinders.
DNA damage-induced apoptosis and detection
Apoptosis was quantitated by assessing the number of cells containing nuclear changes indicative of apoptosis (chromatin condensation and nuclear fragmentation) after staining with DAPI (Lai et al., 2003) . Vector-only and KLF2-transfected OV202 and SKOV3 cells were incubated with MMS and MMC (Sigma-Aldrich, St Louis, MO, USA) at the indicated final concentrations for 12 h. DAPI was then added to each well at a final concentration of 5 mg/ml. After incubation for 20 min in the dark, cells were examined by fluorescence microscopy (Nikon Eclipse TE200; Nikon Corp., Tokyo, Japan) using excitation and emission filters of 380 and 430 nm, respectively. Each treatment was repeated at least three times. Meanwhile, immunoblotting was performed to detect caspase 9 and PARP cleavage (Cell Signal, Beverly, MA, USA).
Luciferase assays of WEE1 promoter activity
After transient transfection, cells were washed with PBS and incubated with Glo lysis buffer (Promega) at room temperature for 5 min. The activity of luciferase was detected using Dual-Luciferase Reporter Assay System (Promega).
Nuclear extract preparation and electrophoretic mobility shift assays
Nuclear protein from KLF2-expressing SKOV3 and vectoronly SKOV3 cells was extracted using the NucBustert Protein Extraction Kit (Novagen, Madison, WI, USA) according to the manufacturer's instruction. Double-strand oligos of WEE1 promoter fragments containing wild-type putative binding sites and mutations were synthesized and labeled with digoxigenin (DIG). EMSAs were performed using the DIG gel shift kit (Roche, Indianapolis, IN, USA) according to the manufacturer's instruction.
Chromatin immunoprecipitation assay
HEK293 cells were transiently transfected with KLF2/myc constructs and ChIP assays were performed using the ChIP assay kit (Upstate, Charlottesville, VA, USA) according to the manufacturer's protocol. Immunoprecipitation (IP) was performed overnight at 41C using 5 mg of anti-myc (Cell Signal, Beverly, MA, USA), mouse IgG, or no antibody. After the final wash, the IP sample was resuspended in 20 ml TE buffer (10 mM Tris, pH 7.5, 1 mM EDTA). PCR reactions were performed using 2 ml of IP sample or 2 ml of a 1 : 100 dilution of input sample, 1.5 mM MgCl 2 , 50 ng of each primer, 200 mM of each dATP, dGTP, dCTP and dTTP, 10% DMSO and 0.5 U of Taq DNA polymerase (Invitrogen) in 20 ml of total volume and 35 cycles of amplification. Actin was used as a negative control.
Site-directed mutagenesis
Mutagenesis was performed on the p252-Luc vector using the GeneTailort Site-Directed Mutagenesis System (Invitrogen). Primers for deletion or substitution were designed as indicated in Table 3 to test the putative KLF2 binding sites. All constructs were verified by sequencing. 
Flow cytometry
Vector-SKOV3, KLF2-SKOV3, Wee1-SKOV3 and KLF2/ Wee1-SKOV3 cells were grown in complete growth medium and incubated with 25 mg/ml MMS for 8 h. Cells were then harvested by trypsinization and centrifugation. Cell pellets were washed three times with PBS and then stained with 20 mg/ml of 7-amino actinomycin D (7AAD; Sigma, St Louis, MO, USA) for 30 min at 41C. Samples were then analysed on a FACScan (BD Bioscience, San Jose, CA, USA). The percentage of apoptotic cells was presented as % of 7-AAD-positive cells in a total of each sample. A total of 20 000 events were acquired for each analysis and data were analysed using CellQuest software (BD Bioscience). 
